New Four-Target drug tested for Tough-to-Treat blood cancer
NCT ID NCT05623982
Summary
This early-stage study is testing a new experimental drug called GNC-038 in adults whose non-Hodgkin's lymphoma has come back or hasn't responded to other treatments. The main goals are to find a safe dose and see if the drug can help control the cancer. The drug is a special antibody designed to attack cancer cells in four different ways at once.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Harbin First Hospital
RECRUITINGHaerbin, Heilongjing, China
Contact
-
Qingdao Central Hospital
RECRUITINGQingdao, Shandong, China
Contact
Conditions
Explore the condition pages connected to this study.